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Introduction: Primary breast lymphoma is an uncommon disease with poor clinical outcome. Breast lymphomas
present less than 0.5% of malignant breast neoplasms and 2.2% of extranodal lymphomas. This study investigated
the clinicopathological features and optimal treatment of PBL.
Case presentations: Clinical records of seven Moroccan PBL patients, treated at the National Institute of Oncology,
Rabat, Morocco, from 2002 to 2010, were reviewed. Six of the patients were women and one a man, with ages
ranging from 32 to 76. Five patients had stage IE and two stage IIE. All of the patients were classified with DLBCL.
Of seven patients, one received a mastectomy and three excision of the breast lesion. Axillary dissection was
performed in three patients. Two patients received chemotherapy followed by radiotherapy, while four received
chemotherapy alone. Complete remission (CR) following primary treatment for all patients with PBL except in two
cases was obtained. In one patient, recurrence occurred.
Conclusions: There is no consensus on the question of how to best treat PBL: Mastectomy offers no benefit in the
treatment of PBL. The combined therapy approach, with chemotherapy and radiotherapy, is the most successful
treatment. PBL is poorly represented in rituximab-containing trials in DLBCL patients; there is not much experience
with this agent in breast DLBCL. Because of the high incidence of central nervous system (CNS) involvement in PBL
patients, many authors strongly believe that patients with aggressive forms of PBL should receive CNS infiltration
prophylaxis.Background
Primary malignant lymphoma of the breast (PLB)
appears to be a rare disease, and few clinicopathological
features of the disease have been discussed in prior stud-
ies. It accounts for 2.2% of extranodal lymphomas and
constitutes 0.04% to 0.5% of malignant breast neoplasms
[1]. The frequency with which the various histopatho-
logical types occur is difficult to determine, because ter-
minology varies among the relatively small cases series
that have been reported. Despite the clinical and radio-
graphic similarities between breast lymphoma and car-
cinoma, the prognosis, as reported in the literature,
varies, as do the applied treatment modalities, which* Correspondence: bourhafourmouna@yahoo.fr
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We retrospectively studied seven cases of PLB of
the breast seen in patients attending the National In-
stitute of Oncology in Rabat, Morocco, between 2002
and 2010, in an attempt to determine the common
clinical features, therapy and prognosis of primary
breast lymphoma.Patients and methods
Clinical data
We report a retrospective study in which the database of
the Department of Medical Oncology at the National In-
stitute of Oncology in Rabat was searched for cases of
breast lymphoma diagnosed over an 8-year period
(2002–2010). A total of seven cases with a diagnosis of
NHL of the breast were enrolled according to the cri-
teria established by Wiseman and Liao: (1) a pathologicalis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Diffuse large B-cell lymphoma. Histologically, the tumor
is composed of lymphoma cells (hematoxylin– eosin stain).
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matous infiltrate and the breast tissue; (2) no evidence
of widespread disease or prior extramammary lymph-
oma; (3) the breast is the principal site of involvement,
but ipsilateral axillary lymph node involvement is ac-
ceptable if both lesions develop simultaneously [2]. Diag-
nosis was made with a core needle or an excisional
biopsy. Histopathological diagnosis was based on the
WHO nomenclature [3]. All patients were staged by
computed tomography scans of the chest, abdomen and
pelvis, and bone marrow biopsy. The staging was based
on the Ann Arbor staging system [4].
Consent and statement of ethical approval
The treatment of each patient was decided by the med-
ical staff of the center, and oral consent was obtained
from the subjects. The study was approved by the insti-
tutional review boards of the National Institute of On-
cology, Cancer Centre in Rabat. This study was
approved by the institutional review boards of the Na-
tional Institute of Oncology in Rabat.
Results
Clinical features
The patients’ characteristics are detailed in Table 1. Of
the seven patients, six were women and one was a man.
The median follow-up time was 36 months (range 12–
60). The median age at presentation was 50 years (range
32–76 years). None of the patients had a previous his-
tory of benign or malignant breast disease. Four patients
had left-sided and two had right-sided disease; one pa-
tient presented bilateral involvement of the breast. The
initial chief complaint in each case was a sign of a tumor
mass, a mass with local inflammation and palpable
lymph nodes. “B” symptoms (10% weight loss, night
sweats, fever) were reported in five patients. The stage
was IE in five patients and IIE in two patients.
Histological classification
Histology revealed diffuse large B-cell lymphoma in all
cases (Figures 1 and 2).Table 1 Clinical characteristics of patients with primary non-H
Case
no.
Age/sex Size of tumor
(cm)
Site of tumor
i
1 32/F 3 Left lower outer quadrant P
2 38/F 7 Left P
3 47/F 4 Right upper outer quadrant P
4 60/F 4 Right upper outer quadrant P
5 55/F - Left P
6 45/F 5 right/3 left Bilateral Palpable m
7 76/M - Left Pa
F female, M male, L left, R right, DLBCL diffuse large B cell lymphoma, IPI InternationTreatment
Three patients had a wide excision of the breast lesion
(one quadrantectomy and two tumorectomies); one pa-
tient had a mastectomy; the other patients underwent
diagnostic biopsies. Axillary dissection was performed in
three patients.
Two patients (case 1, 4) with DLBCL received chemo-
therapy followed by radiotherapy, while four received
chemotherapy alone (cases 2, 3, 5 and 6). Anthracycline-
containing regimens were administered as the initial sys-
temic chemotherapy for six patients with PBL. The
chemotherapy regimen usually included cyclophospha-
mide, doxorubicin, vincristine and prednisone (CHOP).
In two cases, CHOP chemotherapy was combined with
rituximab (CHOP-R). The total radiation dose was usu-
ally 40 Gy (range, 38 to 45 Gy) to the breast alone. The
radiation dose delivered ranged from 36 Gy to 50 Gy
directed to the breast and axilla alone.
Case 3 was interesting. The patient was first diagnosed
with PNET. Thereafter, she was treated with surgeryodgkin’s lymphoma of the breast
Clinical
nformation
Ipsilateral
lymph nodes
Histology Ann/Arbor IPI
alpable mass Present DLBCL IIBE 1
alpable mass Absent DLBCL IBE 1
alpable mass Present DLBCL IIAE 2
alpable mass Absent DLBCL IBE 2
alpable mass – DLBCL IBE 2
asses in both breasts Present (bilateral) DLBCL IIAE 4
lpable lumps Absent DLBCL IBE 1
al Prognostic Index.
Figure 2 Tumor cells indicate a positive immunohistochemical
reaction with CD20.
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ment was completed in eight cycles, and CR was
obtained. The patient then presented with a mass in the
upper outer quadrants of the right breast 2 years after
the diagnosis. Histopathological examination of the bi-
opsy specimen revealed DLBCL of the breast. The pa-
tient received combination therapy of adriamycin,
cyclophosphamide and vincristine (CHOP) every 3 weeks
followed by ICE (ifosfamide, carboplatin and etoposide).
CR was achieved after the completion of six cycles of
chemotherapy. The patient had no specific symptoms
and remained in remission during a follow-up of
24 months.
Survival
Complete remission (CR) following primary treatment
for all patients with PBL except for cases 6 and 7 was
obtained. Recurrence occurred in one patient.
Case 6 died during the second cycle of R-CHOP
chemotherapy because of febrile neutropenia.
Case 7 received no further treatment because of age
and co-morbid conditions. He died of progressive dis-
ease 3 months after surgery.
With a follow-up ranging from 12 to 60 months (me-
dian; 36 months), four out of seven of our patients are
alive and free of disease.
Treatment and follow-up of patients with primary
non-Hodgkin’s lymphoma of the breast are described in
Table 2.
Discussion
PBL is a rare, potentially curable, disease and has been
considered a distinct clinicopathological entity. PBLs
have a reported incidence of 0.04–0.5% of all breastmalignancies [5]. PBLs account for less than 1% of all
patients with NHLs and approximately 1.7% of all extra-
nodal NHLs [1,5]. At our institution, for the past 8 years,
we have treated seven patients for breast involving
lymphoma. The term “primary breast lymphoma” (PBL)
is used to define malignant lymphomas primarily occur-
ring in the breast in the absence of previously detected
lymphoma localizations. Wiseman and Liao [2] are cred-
ited with first defining the clinical criteria for the classi-
fication of PBL.
With the exception of the recently published prospect-
ive Mexican trial (Aviles) and the large study of the
International Extranodal Lymphoma Study Group
(IELSG) with genuine PBLs and sufficient follow-up,
which identified 204 patients [6], in the literature there
were only retrospective studies with a relatively limited
number of patients that have provided some interesting
information [7-11].
The usual clinical feature of a breast lymphoma is a
rapidly expanding, painless mass [11,12]. There is a
slight predilection for the right breast, but the explan-
ation for this remains unclear [12]. The clinical presen-
tation of our patients with breast lymphoma is similar to
that reported by others. Although one of our patients
developed bilateral lymphomas of the breast, an inci-
dence of 6% to 13% has been reported [13].
In our study, the median age was 50 years, which is
comparable to the 5th decade of life published by other
authors [7-11,14,15].
PBL is extremely rare in males, occurring in 1 of our 7
patients, 1 of the 23 patients from the MD Anderson
Cancer Center, 1 of the 25 patients from the Mayo
Clinic [12,16] and none in the other series [9,17].
All histological types of lymphoma have been described.
Primary breast lymphomas are most commonly B-cell
lymphomas; approximately one-half are diffuse large B-
cell lymphoma. Indolent histologies, follicular non-
Hodgkin’s lymphoma or extranodal marginal zone
(MALT) lymphoma occur less commonly [7-11,14-17].
All of our cases also had DLBCL. Disagreement regarding
the treatment of such disease stems from its rareness, with
small case reports; consequently, randomized controlled
trials or clinically controlled trials cannot be carried out.
The prognosis varies, as do the applied treatment modal-
ities, which include surgery, radiotherapy and chemother-
apy used alone or in combination.
Mastectomy has been a common component of PBL ther-
apy for decades and remains a frequent treatment choice in
some reports. Several studies found that mastectomy offered
no benefit in the treatment of primary breast lymphoma
[14,18]. Ideally, surgery should be limited to a biopsy to es-
tablish the correct histological diagnosis, leaving the treat-
ment with curative intent to radiotherapy and chemotherapy.
In our series, mastectomy was performed in only one patient.
Table 2 Treatment and follow-up of patients with primary non-Hodgkin’s lymphoma of the breast
Case
no.
Age/sex Size of tumor
(cm)
Site of tumor Clinical
information
Ipsilateral
lymph nodes
Histology Ann/Arbor IPI
1 32/F 3 Left lower outer quadrant Palpable mass Present DLBCL IIBE 1
2 38/F 7 Left Palpable mass Absent DLBCL IBE 1
3 47/F 4 Right upper outer quadrant Palpable mass Present DLBCL IIAE 2
4 60/F 4 Right upper outer quadrant Palpable mass Absent DLBCL IBE 2
5 55/F - Left Palpable mass – DLBCL IBE 2
6 45/F 5 right/3 left Bilateral Palpable masses
in both breasts
Present
(bilateral)
DLBCL IIAE 4
7 76/M - Left Palpable lumps Absent DLBCL IBE 1
CHOP cyclophosphamide, doxorubicin, vincristine, prednisone; R rituximab; ICE ifosfamide, carboplatin and etoposide; CR complete remission; AW alive and well.
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quadrantectomy and two tumorectomies).
Jennings et al.. [19] reviewed all published PBL reports
from 3 decades (1972–2005). Patient demographics, such
as survival, recurrence and time to follow-up, were
recorded, in addition to surgical, radiation and/or che-
motherapeutic treatment(s). A total of 465 patients were
found. The age range was 17 to 95 years (mean, 54 years).
Follow-up ranged from 1 to 288 months (mean,
48 months). DLBCL was the most common histological
diagnosis (53%). Treatment by mastectomy offered no sur-
vival benefit. Treatment that included radiation therapy in
stage I patients (node negative) showed benefit in both
survival and recurrence rates. Treatment that included
chemotherapy in stage II patients (node positive) showed
benefit in both survival and recurrence rates. Disease-free
survival was 44.5% overall. In conclusion, mastectomy
offers no benefit to the treatment of PBL. Nodal status
predicts outcome and guides the optimal use of radiation
and chemotherapy.
Treatment of primary breast lymphomas follows treat-
ment recommendations for lymphomas of the same
stage and histology in other locations. The choice of
chemotherapeutic regimen should be based upon histo-
logical subtype, disease extent and the individual patient.
In 2008, Ryan et al.. [6] published the results of a retro-
spective international study of 204 eligible patients with the
PBL DLBCL histological subtype attending International
Extranodal Lymphoma Study Group-affiliated institutions
from 1980 to 2003. There was no benefit from mastectomy,
as opposed to biopsy or lumpectomy. Anthracycline-based
chemotherapy was associated with higher overall survival
(OS). Median OS was 8.0 years, and median progression-
free survival (PFS) was 5.5 years. In conclusion, the com-
bination of limited surgery, anthracycline-containing
chemotherapy and involved-field radiotherapy produced
the best outcome in the pre-rituximab era. At a median
follow-up time of 5.5 years, 37% of patients had progressed;
16% in the same or contralateral breast, 5% in the central
nervous system and 14% in other extranodal sites.A similar opinion was expressed by Aviles et al.. [20] on
the basis of their prospective study in which 96 patients
were allocated to radiotherapy with a total dose of 45 Gy
(n= 30), chemotherapy (6×CHOP-21) (n= 32) and com-
bined modality treatment (6 cycles of CHOP and radio-
therapy with a total dose of 30 Gy) (n=34). All included
patients were in the early stage (I or II according to the
Ann Arbor criteria) of PBL, most of them within an inter-
mediate IPI score risk. At 10 years, the actuarial OS was
50, 50 and 76% in the treatment groups, respectively [20].
The authors postulated that combined therapy was the
best method of treating patients with PBL. In our study,
only two patients were treated with combined modality
treatment with a complete response.
The impact of adding rituximab to chemotherapy has
not been studied for primary breast lymphoma. In single
arm prospective study [21], Aviles et al.. evaluated impact
of adding Rituximab to chemotherapy. Patients with early
stage DLBCL-PBL were allocated to receive six cycles of
CEOP-R chemotherapy (cyclophosphamide, epirubicin,
vincristine, prednisone and rituximab) with granulocyte
colony stimulating factor (G-CSF). There were no differ-
ences in either the CR (87%) or EFS (63%) rates compared
to the patients described in their previous study [20].
Although the combination of anthracycline-based
chemotherapy with rituximab should be considered stand-
ard, it appears that the addition of rituximab improves the
outcome of all clinical and molecular subtypes of CD20-
positive diffuse large B-cell lymphoma [22-24].
The role of central nervous system (CNS) prophylaxis in
DLBCL of the breast is controversial. There have been no
prospective trials of CNS prophylaxis in this population.
Case series have reported a high incidence of CNS recur-
rence, estimated at 12 to 27%. Nevertheless, given this
high incidence of CNS recurrence, central nervous system
(CNS) prophylaxis should be considered [6,19,25].
Jeanneret-Sozziet al. [25] performed a multicenter inter-
national retrospective analysis on PBL within the Rare
Cancer Network to assess the clinical profile, treatment
outcome and prognostic factors in primary breast
Table 3 Literature review
Authors Type of
study
Number of
patients
Histology Treatment Follow-up
(years)
Survival
Jennings et al..
2007
Database analysis 465 DLBCL,
follicular
lymphoma,
MALT
Mastectomy +/−
Chemotherapy +/−
Radiotherapy
4 DFS 44.5% overall,
no benefit from
mastectomy
Ryan et al..,
2008
Retrospective 204 DLBCL,
MALT
Surgery,
chemotherapy,
radiotherapy,
combined therapy
5.5 Median OS: 8 years,
Median PFS: 5.5
Aviles et al..,
2005
Prospective 96 DLBCL RT (45 Gy) 10 CR: 66%, EFS: 50%, OS:
50%
CHOP-21 × 6 CR: 59%, EFS: 57%, OS:
50%
CHOP× 6/RT CR: 88%, EFS: 83%, OS:
76%
Aviles et al..,
2007
Prospective Single
arm
32 DLBCL CEOP-R 14 × 6 5.3 CR: 87%, EFS: 63%
Jeanneret-
Sozzi et al..,
2008
Meta-
analysis
84 High-, intermediate-, low-grade
lymphomas
Surgery +/−
Radiotherapy +/−
Chemotherapy
4 OS 5 years 53%,
DFS 41% local
control rate 87%
DLCL diffuse large cell lymphoma; MALT mucosa-associated lymphoid tissue lymphoma; CR complete remission; CHOP cyclophosphamide, doxorubicin, vincristine,
prednisone, CEOP yclophosphamide, epirubicin, vincristine, prednisone; R: rituximab; RT: radiotherapy; OS overall survival; EFS event-free survival; DFS disease-free
survival.
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patients with PBL were treated at 20 institutions. Forty-six
patients had Ann Arbor stage IE, 33 stage IIE, 1 stage IIIE,
2 stage IVE and 2 an unknown stage. Twenty-one under-
went a mastectomy, 39 conservative surgery and 23 bi-
opsy; 51 received radiotherapy (RT) with (n=37) or
without (n= 14) chemotherapy. Median RT dose was
40 Gy. Following this treatment, 10 (12%) patients pro-
gressed locally, and 43 (55%) had a systemic relapses. The
central nervous system (CNS) was the site of relapse in 12
(14%) cases. The 5-year overall survival, lymphoma-
specific survival, disease-free survival and local control
rates were 53%, 59%, 41% and 87%, respectively. Local
control is excellent with RT or the combined modality
treatment, but systemic relapses, including in the CNS,
occur frequently.
In Rayan et al..’s patients [6], one unexpected finding
was that the risk of CNS relapse was relatively low, occur-
ring in only 5% of patients. This is at variance with the
reports of other smaller studies and is considerably lower
than the risk seen in primary testicular DLBCL. It may be
that primary breast DLBCL does not have the same trop-
ism for CNS as testicular DLBCL, and this difference
explains the generally superior survival for patients with
primary breast DLBCL compared with that of patients
with primary testicular DLBCL. However, it is possible
that limiting the eligibility to patients with localized dis-
ease has led to underestimation of the rate of CNS in-
volvement. This result should be considered with caution.
In conclusion, the authors suggested using prophylaxis to
avoid central nervous system involvement.A review of the literature is presented in Table 3.
Conclusions
Primary malignant lymphoma of the breast (PLB) appears
to be a rare disease, and few clinicopathological features
of the disease have been discussed in prior studies. Our
series contained a small sample size, but it is interesting
because it included only DLBCL cases, one case of male
breast lymphoma and one of bilateral breast lymphoma.
No clear consensus concerning the therapy has emerged,
although chemotherapy seems to be the more common
choice, alone or in combination with other treatments. The
choice of chemotherapy regimen and/or use of radiation
therapy (RT) is based upon the histological subtype, disease
extent and individual patient. The prognosis and effective-
ness of individual treatments are generally extrapolated
from therapy for other extranodal lymphomas.
Abbreviations
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